Health-related quality of life in different stages of breast cancer in Serbia.

IF 3.3 4区 医学 Q1 Medicine
M Milovic, T Tamas, I Kolarov Bjelobrk, V Crnobrnja, A Stojsic Milosavljevic, M Paut Kusturica
{"title":"Health-related quality of life in different stages of breast cancer in Serbia.","authors":"M Milovic, T Tamas, I Kolarov Bjelobrk, V Crnobrnja, A Stojsic Milosavljevic, M Paut Kusturica","doi":"10.26355/eurrev_202406_36379","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer is the most commonly diagnosed malignant tumor worldwide, and Serbia ranks first in Europe in standardized breast cancer mortality rate. The aim of this research is to estimate health-related quality of life (HRQoL) and work productivity among patients in different stages of breast cancer in Serbia.</p><p><strong>Subjects and methods: </strong>A total of 175 breast cancer patients attending the breast cancer outpatient clinic at the Oncology Institute of Vojvodina between March 2022 and February 2023 were included in the study. Patients were divided into three mutually exclusive groups: (1) First year after primary breast cancer (Group P), (2) Second and following years after primary breast cancer or recurrence (Group S) and (3) Metastatic disease (Group M). The EQ-5D-3L self-classifier was used to estimate the HRQoL, using the EQ-5D-3L index value and visual analog scale (VAS) score.</p><p><strong>Results: </strong>Мean EQ-5D-3L index value was 0.777 for Group P, and 0.768 for Group S. Patients with metastatic disease reported the lowest EQ-5D index value of 0.646 (p < 0.05). Pain/discomfort, as well as anxiety/depression, were the main drivers of the reduction in HRQoL. Patients in Group M also reported the lowest VAS score of 65.4. Furthermore, the highest percentage of women who sought leave or cited breast cancer as the reason for their early retirement were patients with metastatic disease.</p><p><strong>Conclusions: </strong>HRQoL was most impaired in Group M, and patients with metastatic disease were more likely to take sick leave or retire early due to breast cancer. Delaying or preventing metastatic recurrence could significantly benefit patients' productivity and HRQoL.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 11","pages":"3745-3751"},"PeriodicalIF":3.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European review for medical and pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26355/eurrev_202406_36379","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Breast cancer is the most commonly diagnosed malignant tumor worldwide, and Serbia ranks first in Europe in standardized breast cancer mortality rate. The aim of this research is to estimate health-related quality of life (HRQoL) and work productivity among patients in different stages of breast cancer in Serbia.

Subjects and methods: A total of 175 breast cancer patients attending the breast cancer outpatient clinic at the Oncology Institute of Vojvodina between March 2022 and February 2023 were included in the study. Patients were divided into three mutually exclusive groups: (1) First year after primary breast cancer (Group P), (2) Second and following years after primary breast cancer or recurrence (Group S) and (3) Metastatic disease (Group M). The EQ-5D-3L self-classifier was used to estimate the HRQoL, using the EQ-5D-3L index value and visual analog scale (VAS) score.

Results: Мean EQ-5D-3L index value was 0.777 for Group P, and 0.768 for Group S. Patients with metastatic disease reported the lowest EQ-5D index value of 0.646 (p < 0.05). Pain/discomfort, as well as anxiety/depression, were the main drivers of the reduction in HRQoL. Patients in Group M also reported the lowest VAS score of 65.4. Furthermore, the highest percentage of women who sought leave or cited breast cancer as the reason for their early retirement were patients with metastatic disease.

Conclusions: HRQoL was most impaired in Group M, and patients with metastatic disease were more likely to take sick leave or retire early due to breast cancer. Delaying or preventing metastatic recurrence could significantly benefit patients' productivity and HRQoL.

塞尔维亚不同阶段乳腺癌患者的健康相关生活质量。
目的:乳腺癌是全世界最常见的恶性肿瘤,塞尔维亚的乳腺癌标准化死亡率在欧洲排名第一。本研究旨在评估塞尔维亚不同阶段乳腺癌患者的健康相关生活质量(HRQoL)和工作效率:研究对象包括 2022 年 3 月至 2023 年 2 月期间在伏伊伏丁那省肿瘤研究所乳腺癌门诊就诊的 175 名乳腺癌患者。患者被分为三个互斥组:(1)原发性乳腺癌术后第一年(P 组);(2)原发性乳腺癌术后第二年及以后或复发(S 组);(3)转移性疾病(M 组)。采用EQ-5D-3L自我分类器,利用EQ-5D-3L指数值和视觉模拟量表(VAS)评分来估算HRQoL:P组患者的平均EQ-5D-3L指数值为0.777,S组患者的平均EQ-5D-3L指数值为0.768。疼痛/不适以及焦虑/抑郁是导致 HRQoL 下降的主要原因。M 组患者的 VAS 评分也最低,仅为 65.4 分。此外,在寻求休假或将乳腺癌作为提前退休原因的女性患者中,患转移性疾病的比例最高:结论:M 组患者的 HRQoL 受损最严重,转移性疾病患者更有可能因乳腺癌请病假或提前退休。推迟或预防转移性复发可显著提高患者的工作效率和生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
6.10%
发文量
906
审稿时长
2-4 weeks
期刊介绍: European Review for Medical and Pharmacological Sciences, a fortnightly journal, acts as an information exchange tool on several aspects of medical and pharmacological sciences. It publishes reviews, original articles, and results from original research. The purposes of the Journal are to encourage interdisciplinary discussions and to contribute to the advancement of medicine. European Review for Medical and Pharmacological Sciences includes: -Editorials- Reviews- Original articles- Trials- Brief communications- Case reports (only if of particular interest and accompanied by a short review)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信